What are some possible side effects of using vascepa?

What side effects do patients report most often?

Patients taking Vascepa report muscle and joint pain, swelling in the legs, and swelling in the feet as common complaints. Swelling occurs more than twice as often in Vascepa-treated patients as in those receiving a placebo. Swelling is linked to fluid retention and may affect patients who already have heart failure.

What happens if you combine Vascepa with blood thinners?

Vascepa increases the risk of bleeding when taken with anticoagulant or antiplatelet drugs. Patients on warfarin, aspirin, or clopidogrel should monitor for signs of bleeding such as easy bruising, prolonged cuts, or bleeding gums. Hospital records show higher rates of bleeding-related hospitalizations in patients who this combination.

How does Vascepa affect liver enzymes?

Vascepa raises liver enzymes in some patients. Doctors usually check ALT and AST levels at baseline and after four to eight weeks of treatment. Elevated levels indicate potential liver stress and may require stopping the drug if they keep climbing.

When does Vascepa patent expire?

Vascepa's main compound patent expires in 2030. Companies are already challenging the patent in court. Challenges include claims that the omega-3 acid ethyl esters in Vascepa are obvious and cannot be patented. Companies are seeking early generic launches before 2030.

How do patients compare Vascepa with generic omega-3 supplements?

Patients who turn to generic omega-3 supplements report less consistent results. Generic formulations contain both EPA and DHA, whereas Vascepa contains purified EPA only. The absence of DHA in Vascepa avoids extra triglyceride-raising effects that manchen generic versions produce.